Immatics N.V. (IMTX)

10,74 -0,20 (-1,83%) A partir del 01:52PM EDT. Mercado abierto.

Immatics N.V.

Paul-Ehrlich-Strasse 15
Tübingen 72076
Germany
49 7071 5397 0
https://www.immatics.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 432

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Harpreet Singh Ph.D.	CEO, MD, Member of Management Board & Executive Director	896,49k	N/A	1975
Dr. Toni Weinschenk Ph.D.	Co-Founder & Chief Innovation Officer	N/A	N/A	1974
Mr. Arnd Christ MBA	Chief Financial Officer	N/A	N/A	1966
Mr. Steffen Walter Ph.D.	Chief Operations Officer	N/A	N/A	1977
Mr. Edward A. Sturchio J.D.	General Counsel & Secretary	N/A	N/A	1976
Dr. Carsten Reinhardt M.D., Ph.D.	Chief Development Officer	N/A	N/A	1967
Mr. Cedrik M. Britten M.D.	Chief Medical Officer	N/A	N/A	1976
Mr. Jordan Silverstein	Head of Strategy	N/A	N/A	1980
Dr. Hans-Georg Rammensee Ph.D.	Co-Founder & Member of the Scientific Advisory Board	N/A	N/A	N/A
Mr. Ephraim Hofsäß M.Sc.	Vice President of SEC Reporting & Accounting	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Gobierno corporativo

El ISS Governance QualityScore de Immatics N.V., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.